Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs
Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?
Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.
Organisations must remain agile and decisive across global portfolios, anticipating regulatory changes before they create clinical trial delays.
Editor's Picks
